Vertex Pharmaceuticals Incorporated VRTX
At closeNov 4, 2026, 5:04 PM EST
After hours · Nov 4, 5:04 PM ET
- YTD
- +21.10%
- 1 year
- +30.21%
- Market cap
- 139.07B
- Revenue (ttm)
- 12.95B
- Profit margin
- 30.70%
- EPS (ttm)
- 14.91
- Shares out
- 253.46M
- P/E ratio
- 36.82
- Forward P/E
- 27.45
- YTD return
- +21.10%
- 1-year return
- +30.21%
- Volume
- 1.83M
- Avg volume
- 1.23M
- Open
- 535.63
- Previous close
- 530.76
- Day's range
- 527.38 – 550.77
- 52-week range
- 406.67 – 568.67
- Beta
- 0.28
- Analysts
- Buy
- Price target
- 578.71 (+5.4%)
- Earnings date
- Feb 11, 2027
5D +7.51 (+1.39%)
Key statistics
- Enterprise value
- 134.72B
- PEG ratio
- 2.07
- Price / sales
- 10.74
- Price / book
- 7.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 11.80%
- Free cash flow
- 0
- Total cash
- 6.30B
- Total debt
- 6.48B
- Return on equity
- 20.80%
- Short % of float
- 1.90%
- 50-day average
- 522.98
- 200-day average
- 480.23
Analyst view
Consensus: buy
- Target (low)
- 350.00
- Target (mean)
- 578.71
- Target (high)
- 725.00
- Strong buy6
- Buy20
- Hold4
- Sell1
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 4.78.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 4.38 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 4.82 | 4.76 | -0.06 | -1.24% |
| Aug 3, 2026 | Jun 30, 2026 | 4.74 | 4.73 | -0.01 | -0.21% |
| May 4, 2026 | Mar 31, 2026 | 4.24 | 4.47 | +0.23 | +5.42% |
| Feb 12, 2026 | Dec 31, 2025 | 5.11 | 5.03 | -0.08 | -1.57% |
| Nov 3, 2025 | Sep 30, 2025 | 4.57 | 4.80 | +0.23 | +5.03% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Barclays | main | Overweight | Overweight |
| Nov 3, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 3, 2026 | Goldman Sachs | main | Buy | Buy |
| Nov 3, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 3, 2026 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Nov 3, 2026 | UBS | main | Buy | Buy |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vrtx.com
News
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626
Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...'
Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by AIA Group Ltd
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance
Aware Super Pty Ltd as trustee of Aware Super Acquires 11,017 Shares of Vertex Pharmaceuticals Incorporated $VRTX Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725
Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660
Scotiabank Maintains Sector Outperform on Vertex Pharmaceuticals, Raises Price Target to $660
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $640
Your note
Sign in to keep a note on VRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTSHULER DAVID | Officer | Stock Award(Grant) | Jan 21, 2026 | 34,477 |
| ARBUCKLE STUART A | Chief Operating Officer | Stock Award(Grant) | May 12, 2025 | 100,751 |
| ATKINSON EDWARD MORROW III | Chief Technology Officer | Sale | Feb 24, 2026 | 18,432 |
| KEWALRAMANI RESHMA | Chief Executive Officer | Sale | Feb 26, 2026 | 98,278 |
| LEIDEN JEFFREY M | Officer and Director | Stock Award(Grant) | Feb 16, 2026 | 38,784 |
| LIU JOY | Officer | Sale | Jun 30, 2026 | 19,131 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Capital World Investors | 10.29% | 26,115,014 | 14.34B | Jun 29, 2026 |
| Blackrock Inc. | 9.50% | 24,109,373 | 13.24B | Jun 29, 2026 |
| Capital Research Global Investors | 7.68% | 19,490,637 | 10.70B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 16,580,713 | 9.10B | Jun 29, 2026 |
| State Street Corporation | 4.68% | 11,871,459 | 6.52B | Jun 29, 2026 |
| Invesco Ltd. | 3.17% | 8,043,052 | 4.42B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund of America | 5.09% | 12,908,237 | 7.09B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,058,128 | 4.42B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 6,576,510 | 3.61B | Jun 29, 2026 |
| AMERICAN BALANCED FUND | 2.14% | 5,428,865 | 2.98B | Sep 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 5,294,126 | 2.91B | Sep 29, 2026 |
| Amcap Fund | 1.87% | 4,734,921 | 2.60B | Sep 29, 2026 |
